Free Trial
→ You cannot escape this reality (From Porter & Company) (Ad)tc pixel Free ENTO Stock Alerts

Entero Therapeutics (ENTO) Competitors

Entero Therapeutics logo
$4.84 +0.23 (+4.99%)
As of 05/22/2026
Compare

ENTO vs. ALVR, TXMD, CELU, ALLR, and SNSE

Should you buy Entero Therapeutics stock or one of its competitors? MarketBeat compares Entero Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entero Therapeutics include AlloVir (ALVR), TherapeuticsMD (TXMD), Celularity (CELU), Allarity Therapeutics (ALLR), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical products" industry.

How does Entero Therapeutics compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

AlloVir's return on equity of -71.03% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
AlloVirN/A -71.03% -61.27%
Entero Therapeutics N/A -461.02%-14.72%

66.1% of AlloVir shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Entero Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AlloVirN/AN/A-$190.42M-$20.23N/A
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AlloVir
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Entero Therapeutics' average media sentiment score of 0.75 beat AlloVir's score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
AlloVir Neutral
Entero Therapeutics Positive

AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

Summary

Entero Therapeutics beats AlloVir on 6 of the 10 factors compared between the two stocks.

How does Entero Therapeutics compare to TherapeuticsMD?

Entero Therapeutics (NASDAQ:ENTO) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Entero Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

TherapeuticsMD has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A
TherapeuticsMD$3.02M8.12-$570K$0.0635.33

TherapeuticsMD has a net margin of 5.34% compared to Entero Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Entero TherapeuticsN/A -461.02% -14.72%
TherapeuticsMD 5.34%0.32%0.23%

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
TherapeuticsMD
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Entero Therapeutics' average media sentiment score of 0.75 beat TherapeuticsMD's score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Entero Therapeutics Positive
TherapeuticsMD Neutral

Summary

TherapeuticsMD beats Entero Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Entero Therapeutics compare to Celularity?

Celularity (NASDAQ:CELU) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

19.0% of Celularity shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Entero Therapeutics' average media sentiment score of 0.75 beat Celularity's score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Celularity Neutral
Entero Therapeutics Positive

Celularity has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

Entero Therapeutics has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Celularity-345.45% N/A -77.94%
Entero Therapeutics N/A -461.02%-14.72%

Celularity currently has a consensus target price of $6.00, indicating a potential upside of 589.58%. Given Celularity's stronger consensus rating and higher possible upside, research analysts plainly believe Celularity is more favorable than Entero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celularity
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Entero Therapeutics has lower revenue, but higher earnings than Celularity. Entero Therapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celularity$26.55M0.95-$91.72M-$3.33N/A
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A

Summary

Celularity beats Entero Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Entero Therapeutics compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Allarity Therapeutics' return on equity of -109.94% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Allarity TherapeuticsN/A -109.94% -47.27%
Entero Therapeutics N/A -461.02%-14.72%

Allarity Therapeutics has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Allarity Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allarity Therapeutics$320K88.00-$11.23M-$0.72N/A
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A

11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 0.1% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Allarity Therapeutics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

Allarity Therapeutics presently has a consensus price target of $9.75, indicating a potential upside of 450.85%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allarity Therapeutics is more favorable than Entero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allarity Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Entero Therapeutics' average media sentiment score of 0.75 beat Allarity Therapeutics' score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Allarity Therapeutics Neutral
Entero Therapeutics Positive

Summary

Allarity Therapeutics beats Entero Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Entero Therapeutics compare to Sensei Biotherapeutics?

Entero Therapeutics (NASDAQ:ENTO) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Sensei Biotherapeutics had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 2 mentions for Sensei Biotherapeutics and 0 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.75 beat Sensei Biotherapeutics' score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Entero Therapeutics Positive
Sensei Biotherapeutics Neutral

Entero Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.18, meaning that its share price is 118% less volatile than the broader market.

Entero Therapeutics' return on equity of -461.02% beat Sensei Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Entero TherapeuticsN/A -461.02% -14.72%
Sensei Biotherapeutics N/A -803.00%-256.50%

Entero Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A
Sensei BiotherapeuticsN/AN/A-$21.08M-$142.72N/A

Sensei Biotherapeutics has a consensus target price of $45.00, indicating a potential upside of 152.95%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Entero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Sensei Biotherapeutics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Summary

Entero Therapeutics beats Sensei Biotherapeutics on 7 of the 13 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENTO vs. The Competition

Export
MetricEntero TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.69M$3.37B$6.46B$12.34B
Dividend YieldN/A2.26%2.76%5.28%
P/E Ratio-2.8618.7421.0025.66
Price / SalesN/A323.98562.1886.31
Price / CashN/A125.1743.4956.67
Price / Book-1.987.0910.417.14
Net Income-$18.06M$24.45M$3.57B$335.98M
7 Day Performance28.04%6.38%6.40%4.11%
1 Month Performance113.22%2.43%3.54%2.52%
1 Year Performance324.67%62.98%34.14%35.04%

Entero Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENTO
Entero Therapeutics
0.0601 of 5 stars		$4.84
+5.0%		N/A+324.7%$7.69MN/AN/A9
ALVR
AlloVir
N/A$4.83
+2.8%		N/A+76.3%$24.36MN/AN/A110
TXMD
TherapeuticsMD
0.6037 of 5 stars		$2.11
+1.4%		N/A+46.2%$24.08M$3.02M35.17420
CELU
Celularity
1.335 of 5 stars		$0.90
+8.9%		$6.00
+567.7%		-62.0%$23.89M$26.55MN/A220
ALLR
Allarity Therapeutics
2.0727 of 5 stars		$1.66
+11.4%		$9.75
+487.3%		+71.8%$23.71M$345KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ENTO) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel